Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTA02A in Healthy Adults and Patients With Chronic Hepatitis B
NCT07903831Phase 1Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Oct 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hepatitis B (HBV) comparing SCTA02A with Placebo (2 arms). Primary endpoints: Treatment-Related Adverse Events at 16 weeks, Maximum Tolerated Dose at 16 weeks and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SCTA02A
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07903831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903831.